Skip to main content
Blog-Banner

Medical Devices – USA, Europe, Asia and ROW Regulatory News – Apr 2024



USA

https://www.fda.gov/regulatory-information/search-fda-guidance-documents/data-standards-catalog



EUROPE

The IB shall contain the clinical and non-clinical information on the investigational device that is relevant for the investigation and available at the time of application. The information shall be presented in a concise, simple, objective, balanced, and non-promotional form that enables a potential investigator and the investigation site team, to understand it and make his/her own unbiased benefit-risk analysis of the appropriateness of exposing study participants to the investigational device. Further the IB should contain sufficient information to allow safe and correct use of the device.

The publication is designed to support sponsors in developing their IB by describing in greater detail what type of information is expected in the respective IB sections, in order to preempt questions from the competent authorities during the assessment of the clinical investigation application. The guideline is based on the requirements of both the MDR and ISO14155:2020 as well as experience from the competent authorities.

MDCG 2022-9 / Rev.1 – Summary of safety and performance Template

Regulation (EU) 2017/746 on in vitro diagnostic medical devices (the IVDR) requires that the manufacturer shall draw up a summary of safety and performance (SSP) for class C and D devices, other than devices for performance studies. The SSP shall be validated by a notified body (NB) and made available to the public via the European database on medical devices (Eudamed).

The SSP should include information dedicated to the intended user, and if relevant, the patient. The SSP shall be kept revisiond in Eudamed. If the device is not intended for self-testing, the SSP should be dedicated to the professional user. If the device is intended for self-testing, the SSP should be written in a way that is clear to the patients/lay persons, for instance taking into consideration the age of the targeted population.

MDCG 2024-4 – Safety reporting in performance studies of in vitro diagnostic medical devices under Regulation (EU) 2017/746

Safety reporting in performance studies of in vitro diagnostic medical devices (IVDs) shall be performed in line with the requirements of Article 76(2) of Regulation (EU) 2017/746 – In Vitro Diagnostic Medical Device Regulation (IVDR). The sponsor shall report without delay to all Member States in which a performance study is being conducted all of the following by means of the electronic system referred to in IVDR Article 69

For post-market performance follow-up (PMPF) studies of CE marked devices1 used within the intended purpose covered by the CE marking, reporting requirements of IVDR Articles 76(5-6) apply. This means that the vigilance provisions laid down in IVDR Articles 82 to 85 and in the acts adopted pursuant to IVDR Article 86 apply to PMPF studies.

A Study and dashboard on reprocessing and reuse of single-use-devices in the EU



CHINA

This review point applies to multiport laparoscopic surgery systems (referred to as surgical systems). According to the current “Medical Device Classification Catalog”, the classification code of this type of product is 01-07-03, and the management category is Class III.



FINLAND

The amendment decree introduces new obligations to provide advance information related to the availability of devices to the authorities when the interruptions in the availability of the device or the end of production are estimated to cause significant disruptions to healthcare.

The changes regarding the transitional periods of the IVD Regulation are related to the additional time given to manufacturers for the application of the new regulatory framework. The new transition periods depend on the type of device and especially the risk category according to the IVD Regulation.

Manufacturer of medical devices – make sure to take advantage of the extension of the transition period

The Medical Device Regulation (EU) 2017/745 (MD Regulation) allows the manufacture of devices in accordance with previous directives for a long time, but only under certain conditions.



GERMANY

Request for classification and/or delimitation

For a delimitation or classification decision by the BfArM, an informal application for classification and/or delimitation is required to be submitted to the BfArM in accordance with Section 6 Paragraph 2 of the Medical Devices Law Implementation Act (MPDG). In principle, a notified body, the manufacturer, its authorized representative or the responsible state agency are entitled to apply.

The delimitation of a product is based on the definition of medical devices in Article 2 No. 1 of Regulation (EU) 2017/745 (Medical Device Regulation, MDR). The classification is carried out according to the classification rules of Annex VIII of the MDR.

Incident reporting by manufacturer and authorized representatives

Until the European database for medical devices is fully functional in accordance with Article 33 of Regulation (EU) 2017/745 (MDR), the reporting form below is required to be used

  • Reports of serious incidents in accordance with Article 87 MDR by manufacturers (for medical devices excluding in-vitro diagnostics)
  • Reports of serious incidents in accordance with Article 82 of Regulation (EU) 2017/746 – IVDR (for in-vitro diagnostics)


HONG KONG



HUNGARY

Guidance for the Transition of clinical trials from the Clinical Trials Directive to the Clinical Trials Regulation

From 31 January 2025 onwards sponsors are requested to transition to the legal framework of the CTR the ongoing clinical trials that are currently under the regime of the Clinical Trials Directive (CTD) and expected to be ongoing after 30 January 2025.



PORTUGAL

The diploma establishes, among others, a set of rules applicable to economic operators and health institutions that manufacture and use devices in their respective facilities, as well as rules relating to the use and traceability of devices, the designation and supervision of the activities of notified bodies and market surveillance and inspection.



PHILIPPINES

Pursuant to Section 35(b) of RA No. 11223 on Ethics in Public Health Policy and Practice, all FDA-licensed manufacturers, traders, repackers, distributor-importers, and distributor- wholesalers of drug, medical devices, and biological products, including vaccines, and medical supplies registered with the FDA are mandated to collect and track all financial relationships with healthcare providers and healthcare professionals and report these to the Department of Health, through the FDA.



SAUDI ARABIA

Update: Regulations and Requirements for the clearance of medicines, pharmaceutical products, medical devices, and food products that arrive for pilgrims use

The updates in this version are as follows:

  • Create a new email to receive application Hajj@sfda.gov.sa
  • Change the email to Hajj@sfda.gov.sa
  • Applications will be received via External Hajj Unified System of the Ministry of Hajj.


SOUTH KOREA



SPAIN

The AEMPS participates in the European action JAMS 2.0 to carry out joint inspections of medical devices

The Spanish Agency for Medicines and Health Products (AEMPS) participates in the JAMS 2.0 joint action, framed within the EU4Health program of the European Commission, which aims to improve European coordination, surveillance and control of the health products market and medical devices for in vitro diagnosis. The Agency is part of four of the eight work packages of this initiative and is the leader of one of them, work package 7 (WP7) to develop a common methodology for the implementation of European campaigns. market control.



SRILANKA

All importers of Medical Devices are hereby informed that NMRA will terminate the email confirmation process for the foreign manufacturing site application (FMSA). Hence, you can submit FMSA application without the email confirmation which is issued by the Head of Medical Device Division/NMRA with effect from 22nd of April 2024.



SWITZERLAND

Information sheet Medical Device Software



THAILAND



UNITED KINGDOM

To carry out a clinical investigation as part of the process to obtain a UKCA / CE / CE UKNI marking for your medical device. is required to inform the MHRA is there any planning to do clinical investigation at least 60 days before starting your investigation. Applications are submitted electronically using the Integrated Research Application System (IRAS). A notification to the MHRA will not be required for medical devices that are UKCA / CE / CE UKNI marked for the purpose that is under investigation.

Update: Guidance on Borderlines with medical devices and other products in Great Britain

Tags: , , , , , , ,
Get the latest updates from Vistaar

    Subscribe

    Share the Blog:

    CONNECT WITH US

      Subscribe
      The First Step

      Let's talk about how Vistaar can help you